FTH Faeth Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1829802 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-775.6%
TTM EPS YoY-17.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-229.6%
ROA-204.7%
ROIC (approx.)-214.2%
Asset turnover—
Leverage & solvency
Liabilities / assets6.2%
Debt / equity0.00x
Current ratio16.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-162.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $10.35M | $9.21M | $19.71M | $2.79M | $2.31M | $2.67M | $3.55M | $2.83M |
| Operating income | -$22.09M | -$18.39M | -$170.63M | -$4.96M | -$4.85M | -$5.21M | -$7.27M | -$8.27M |
| Interest expense | — | — | — | $3,000 | $6,000 | $10,000 | $13,000 | $17,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$20.40M | -$16.01M | -$170.24M | -$4.72M | -$4.57M | -$4.94M | -$6.86M | -$7.77M |
| EBITDA | -$22.07M | -$18.36M | -$170.60M | -$4.93M | -$4.82M | -$5.17M | -$7.24M | -$8.13M |
| EPS (basic) | -0.79 | -2.84 | -131.45 | — | -3.62 | -3.91 | -5.45 | — |
| EPS (diluted) | -0.79 | -2.84 | -131.45 | — | -3.62 | -3.91 | -5.45 | — |
| Weighted avg. shares (diluted) | 25.84M | 5.64M | 1.30M | — | 1.26M | 1.26M | 1.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.18M | $26.90M | $152.32M | $8.67M | $10.56M | $12.56M | $9.88M | $9.99M |
| Short-term investments | $160.62M | $159.54M | $50.47M | $12.52M | $14.48M | $16.07M | $24.45M | $31.34M |
| Current assets | $177.84M | $188.66M | $204.23M | $21.51M | $25.79M | $29.57M | $35.68M | $41.93M |
| PP&E, net | $1,000 | $44,000 | $69,000 | $82,000 | $112,000 | $143,000 | $159,000 | $417,000 |
| Goodwill | $0 | $0 | $0 | — | — | — | — | — |
| Total assets | $178.95M | $189.31M | $205.38M | $22.90M | $27.59M | $31.78M | $38.27M | $45.36M |
| Current liabilities | $11.03M | $9.58M | $14.19M | $4.25M | $4.44M | $3.87M | $5.23M | $5.45M |
| Total liabilities | $11.09M | $9.58M | $14.19M | $4.31M | $4.58M | $4.47M | $6.29M | $6.97M |
| Shareholders' equity | $161.10M | $172.96M | -$137.29M | $18.59M | $23.01M | $27.31M | $31.99M | $38.39M |
| Shares outstanding | 25.84M | 25.83M | 1.34M | 1.26M | 1.26M | 1.26M | 25.21M | 1.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.00M | -$15.67M | -$10.73M | -$3.86M | -$3.59M | -$5.91M | -$7.09M | -$5.79M |
| Capital expenditure | $3,000 | $0 | $6,000 | $0 | $0 | $16,000 | $0 | $0 |
| Free cash flow | -$13.01M | -$15.67M | -$10.74M | -$3.86M | -$3.59M | -$5.92M | -$7.09M | -$5.79M |
| Investing cash flow | $175,000 | -$108.07M | -$31.44M | $2.08M | $1.74M | $8.76M | $7.19M | -$3.15M |
| Financing cash flow | $104,000 | -$1.68M | $185.83M | -$111,000 | -$152,000 | -$168,000 | -$214,000 | -$194,000 |
| Depreciation & amortization | $17,000 | $25,000 | $29,000 | $30,000 | $30,000 | $32,000 | $30,000 | $139,000 |
| Stock-based compensation | $8.52M | $4.48M | $12.90M | $295,000 | $254,000 | $264,000 | $461,000 | $391,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.